FES in Uterine Cancer

Brief description of study

Primary Objectives

Evaluate utility of FES PET/CT to detect estrogen receptor (ER+) uterine cancer lesions in patients with recurrent or metastatic uterine cancer Secondary Objectives

        Evaluate utility of FES PET/CT compared to standard axial cross-sectional imaging and/or FDG PET/CT when available to establish tumor heterogeneity and staging
        Correlate FES uptake with estimate of progression-free survival 
        Correlate FES PET/CT uptake measures with standard and experimental pathology (e.g. estrogen receptor-alpha, estrogen receptor-beta)
        In patients who receive a second FES PET/CT scan, compare FES uptake in patients at initial scan and at progression Estrogen receptor uptake on PET/CT in patients with uterine cancer blood based lab markers of estrogen activity(estradiol, SHBG, etc)

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Medical Research
Age: - 99 Years
Gender: All

TBD

Updated on 09 Mar 2024. Study ID: 852782

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).